Imperial College London
Alternate

Professor Toby Maher

Faculty of Medicine, National Heart & Lung Institute

Professor of Interstitial Lung Disease
 
 
 
//

Contact

 

+44 (0)20 7594 2151t.maher

 
 
//

Assistant

 

Ms Georgina Moss +44 (0)20 7594 2151

 
//

Location

 

364Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Gayle:2020:10.1007/s12325-020-01330-0,
author = {Gayle, A and Schoof, N and Alves, M and Clarke, D and Raabe, C and Das, P and Del, Galdo F and Maher, TM},
doi = {10.1007/s12325-020-01330-0},
journal = {Advances in Therapy},
pages = {2460--2476},
title = {Healthcare resource utilization among patients in England with systemic sclerosis-associated interstitial lung disease: a retrospective database analysis.},
url = {http://dx.doi.org/10.1007/s12325-020-01330-0},
volume = {37},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - INTRODUCTION: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) places a substantial burden on patients and healthcare systems. The objectives of this study were to describe clinical characteristics and assess healthcare resource utilization and costs of patients with SSc-ILD in England, compared with patients with non-pulmonary organ involvement related to SSc (SSc-OOI). METHODS: This population-based retrospective study used data from the Clinical Practice Research Datalink linked to Hospital Episode Statistics. Data were extracted from medical records dated January 1, 2005 to March 31, 2016. Patients with SSc were identified and placed in subgroups based on organ involvement: SSc-ILD, SSc-OOI, and both (SSc-ILD-OOI). Patients with SSc-ILD-OOI were included in both the SSc-ILD and SSc-OOI subgroups. All-cause healthcare costs, excluding medication costs, were calculated to 2016 British pounds sterling (£). RESULTS: This study included 675 patients with SSc: 174 (26%) had neither ILD nor other organ involvement (OOI); 127 (19%) had SSc-ILD; 477 (71%) had SSc-OOI; 103 (15%) had SSc-ILD-OOI. Age-weighted median [interquartile range (IQR)] annual healthcare costs per patient were: £1496 (£664-£2817) in SSc only; £6375 (£3451-£15,041) in SSc-ILD; £4084 (£1454-£10,105) in SSc-OOI; £6632 (£4023-£17,009) in SSc-ILD-OOI. In multivariate analysis, older age at diagnosis, diagnosis of anemia, and number of comorbid diseases were associated with higher yearly healthcare costs. CONCLUSION: The annual healthcare cost for patients with SSc-ILD is substantial, and higher than that of patients with SSc-OOI or SSc only. These results quantify the economic burden of SSc-ILD in a real-world setting, and highlight the need for treatment of this disease.
AU  - Gayle,A
AU  - Schoof,N
AU  - Alves,M
AU  - Clarke,D
AU  - Raabe,C
AU  - Das,P
AU  - Del,Galdo F
AU  - Maher,TM
DO  - 10.1007/s12325-020-01330-0
EP  - 2476
PY  - 2020///
SN  - 0741-238X
SP  - 2460
TI  - Healthcare resource utilization among patients in England with systemic sclerosis-associated interstitial lung disease: a retrospective database analysis.
T2  - Advances in Therapy
UR  - http://dx.doi.org/10.1007/s12325-020-01330-0
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32319038
UR  - https://link.springer.com/article/10.1007%2Fs12325-020-01330-0
UR  - http://hdl.handle.net/10044/1/79058
VL  - 37
ER  -
Download